Table 1.
Demographic and clinicopathological characteristics between EORC and LORC
| Characteristics | All N = 1042 | EORC N = 264 | LORC N = 778 | P value |
|---|---|---|---|---|
| Agea, years | 58.00 [49.00-66.00] | 43.00 [37.00-46.00] | 62.00 [57.00-68.00] | <0.001∗ |
| Gender | 0.153 | |||
| Female | 359 (34.45) | 101 (38.26) | 258 (33.16) | |
| Male | 683 (65.55) | 163 (61.74) | 520 (66.84) | |
| BMIa | 22.60 [20.73-24.75] | 22.68 [20.54-24.73] | 22.58 [20.78-24.75] | 0.898 |
| Location | 0.076 | |||
| Upper | 153 (14.68) | 28 (10.61) | 125 (16.07) | |
| Mid | 495 (47.50) | 127 (48.11) | 368 (47.30) | |
| Low | 394 (37.81) | 109 (41.29) | 285 (36.63) | |
| Clinical stage | 0.190 | |||
| I | 147 (14.11) | 32 (12.12) | 115 (14.78) | |
| II | 313 (30.04) | 72 (27.27) | 241 (30.98) | |
| III | 582 (55.85) | 160 (60.61) | 422 (54.24) | |
| cT stage | 0.415 | |||
| ≤T2 | 185 (17.75) | 42 (15.91) | 143 (18.38) | |
| >T2 | 857 (82.25) | 222 (84.09) | 635 (81.62) | |
| cN stage | 0.066 | |||
| Negative | 467 (44.82) | 105 (39.77) | 362 (46.53) | |
| Positive | 575 (55.18) | 159 (60.23) | 416 (53.47) | |
| Pretreatment CEA | 0.021∗ | |||
| Negative | 626 (62.79) | 174 (69.05) | 452 (60.67) | |
| Positive | 371 (37.21) | 78 (30.95) | 293 (39.33) | |
| Pretreatment CA19-9 | 0.542 | |||
| Negative | 867 (87.31) | 215 (86.00) | 652 (87.75) | |
| Positive | 126 (12.69) | 35 (14.00) | 91 (12.25) | |
| Differentiation | 0.005∗ | |||
| Well/moderately | 865 (97.30) | 198 (94.29) | 667 (98.23) | |
| Poor/undifferentiated | 24 (2.70) | 12 (5.71) | 12 (1.77) | |
| pT stage | 0.698 | |||
| ≤T2 | 402 (38.58) | 105 (39.77) | 297 (38.17) | |
| >T2 | 640 (61.42) | 159 (60.23) | 481 (61.83) | |
| pN stage | 0.165 | |||
| Negative | 728 (69.87) | 175 (66.29) | 553 (71.08) | |
| Positive | 314 (30.13) | 89 (33.71) | 225 (28.92) | |
| pTNM | 0.155 | |||
| 0/I | 357 (34.29) | 93 (35.23) | 264 (33.98) | |
| II | 371 (35.64) | 82 (31.06) | 289 (37.19) | |
| III | 371 (35.64) | 89 (33.71) | 224 (28.83) | |
| LVI | 0.757 | |||
| Negative | 884 (92.86) | 225 (92.21) | 659 (93.08) | |
| Positive | 68 (7.14) | 19 (7.79) | 49 (6.92) | |
| Neoadjuvant therapy | 0.003∗ | |||
| No | 585 (56.14) | 127 (48.11) | 458 (58.87) | |
| Yes | 457 (43.86) | 137 (51.89) | 320 (41.13) | |
| Adjuvant therapy | <0.001∗ | |||
| No | 419 (40.21) | 73 (27.65) | 346 (44.47) | |
| Yes | 623 (59.79) | 191 (72.35) | 432 (55.53) | |
| Local recurrence | 0.516 | |||
| No | 976 (93.67) | 250 (94.70) | 726 (93.32) | |
| Yes | 66 (6.33) | 14 (5.30) | 52 (6.68) | |
| Distant metastasis | 0.680 | |||
| No | 836 (80.23) | 209 (79.17) | 627 (80.59) | |
| Yes | 206 (19.77) | 55 (20.83) | 151 (19.41) | |
| Total recurrence | >0.999 | |||
| No | 806 (77.35) | 204 (77.27) | 602 (77.38) | |
| Yes | 236 (22.65) | 60 (22.73) | 176 (22.62) | |
| DFSa | 63.60 [34.44-74.95] | 64.85 [38.30-75.93] | 63.17 [33.38-74.72] | 0.298 |
Unless stated otherwise, data are numbers of patients, with percentages in parentheses. P values represent the comparison of clinicopathologic variables between two groups.
BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; cN stage, clinical nodal stage; cT stage, clinical tumor stage; DFS, disease-free survival; EORC, early-onset rectal cancer; LORC, late-onset rectal cancer; LVI, lymphovascular invasion; pN stage, pathological nodal stage; pT stage, pathological tumor stage; pTNM, pathological TNM stage.
a
Data are medians, with IQRs in parentheses.
∗
P value was <0.05 and considered statistically significant.